• linkedin
  • Increase Font
  • Sharebar

    AUA 2016: Experts offer guidance on the meeting


    Sexual Dysfunction

    Arthur L. Burnett, II, MD, MBADr. BurnettArthur L. Burnett, II, MD, MBA, told Urology Times that a review of this year’s sexual dysfunction abstracts reveals several important themes in sexual medicine, including hypogonadism and Peyronie’s disease.

    “The topic of male hypogonadism and testosterone therapy remains in mainstream discussion, with studies further defining at-risk populations and risk factors for testosterone deficiency as well as examining long-term effects of testosterone therapy on sexual function, urinary function and prostate health, and cardiovascular health,” said Dr. Burnett, professor of urology at Johns Hopkins University, Baltimore.

    “For Peyronie’s disease, treatment with intralesional collagenase clostridium histolyticum (XIAFLEX) has been further evaluated with reports on real-world experiences that heighten understanding of both its therapeutic role and outcomes,” he added.

    Below are the key sexual dysfunction abstracts from this year, according to Dr. Burnett:

    PD50-02: Effects of long-term testosterone undecanoate injections (TU) on urinary and sexual function in hypogonadal men: real-life data from a controlled registry study
    Ahmad Haider


    PD50-03: Cardiovascular events and prostate cancer diagnoses in men treated with testosterone replacement therapy
    Christopher Wallis


    PD45-02: Impact of number of cycles of Collagenase Clostridium Histolyticum on outcomes in patients with Peyronie’s disease
    James Anaissie

    Next: BPH/LUTS

    Benjamin P. Saylor
    Saylor is content managing editor for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available